达比加群酯与华法林用于非瓣膜性心房颤动患者抗凝的有效性与安全性比较

发布时间：2018-02-13 08:28

本文关键词： 达比加群酯华法林非瓣膜性心房颤动抗凝有效性安全性　出处：《中国药房》2017年33期 　论文类型：期刊论文

【摘要】：目的:比较达比加群酯与华法林用于非瓣膜性心房颤动(NVAF)患者抗凝的有效性和安全性。方法:回顾性分析360例NVAF患者资料,按用药方案的不同分为对照组(180例)和观察组(180例)。对照组患者给予华法林钠片,起始剂量2.5 mg,口服,每日1次,根据国际标准化比值(INR)调整剂量。观察组患者给予达比加群酯胶囊150 mg,每日2次,温水送服,餐时或餐后服用。观察两组患者治疗前与治疗1、3个月后丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)水平、INR及不良反应发生情况。结果:两组患者治疗前后ALT、AST水平比较,差异均无统计学意义(P0.05)。治疗前,两组患者INR比较,差异无统计学意义(P0.05)。治疗1、3个月后,对照组患者INR均显著高于同组治疗前,差异有统计学意义(P0.05);观察组患者治疗前后比较,差异均无统计学意义(P0.05),但两组患者INR值均在正常范围内。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:达比加群酯治疗NVAF患者的抗凝有效性显著优于华法林,且两药的安全性相当。
[Abstract]:Objective: to compare the anticoagulant efficacy and safety of dabiquant and warfarin in patients with nonvalvular atrial fibrillation (NV). Methods: the data of 360 patients with NVAF were retrospectively analyzed. The patients in the control group were given warfarin sodium tablets at an initial dose of 2.5 mg, once a day, and 180 patients in the observation group were given warfarin sodium tablets. According to the international standard ratio (INR), the patients in the observation group were given 150 mg of dabiganate capsules twice a day, and given warm water, and the patients in the observation group were given warm water. To observe the levels of alanine aminotransferase (alt) and aspartate aminotransferase (AST) and the incidence of adverse reactions before and after treatment in the two groups. Results: before and after treatment, the levels of alt and AST were compared between the two groups. Before treatment, there was no significant difference in INR between the two groups (P 0.05). After 1 month and 3 months of treatment, the INR of the control group was significantly higher than that of the control group before and after treatment, and the difference was statistically significant (P 0.05), while that of the observation group before and after treatment was significantly higher than that of the control group (P 0.05), while that of the control group was significantly higher than that of the control group (P 0.05) before and after treatment. There was no significant difference in INR between the two groups, but the INR values of the two groups were within the normal range. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: the anticoagulant efficacy of dabib plus Qun ester in the treatment of NVAF patients is significantly better than that of warfarin, and there is no significant difference in the incidence of adverse reactions between the two groups. And the safety of the two drugs is equal.
【作者单位】：河南大学淮河医院心内科;开封大学医学院;
【分类号】：R541.75

【相似文献】